Regulation of Extrinsic Pathway Factor Xa Formation by Tissue Factor Pathway Inhibitor
Overview
Authors
Affiliations
Tissue factor (TF) pathway inhibitor (TFPI) regulates factor X activation through the sequential inhibition of factor Xa and the VIIa.TF complex. Factor Xa formation was studied in a purified, reconstituted system, at plasma concentrations of factor X and TFPI, saturating concentrations of factor VIIa, and increasing concentrations of TF reconstituted into phosphatidylcholine:phosphatidylserine membranes (TF/PCPS) or PC membranes (TF/PC). The initial rate of factor Xa formation was equivalent in the presence or absence of 2.4 nM TFPI. However, reaction extent was small (<20%) relative to that observed in the absence of TFPI, implying the rapid inhibition of VIIa.TF during factor X activation. Initiation of factor Xa formation using increasing concentrations of TF/PCPS or TF/PC in the presence of TFPI yielded families of progress curves where both initial rate and reaction extent were linearly proportional to the concentration of VIIa.TF. These observations were consistent with a kinetic model in which the rate-limiting step represents the initial inhibition of newly formed factor Xa. Numerical analyses of progress curves yielded a rate constant for inhibition of VIIa.TF by Xa.TFPI (>10(8) M-1.s-1) that was substantially greater than the value (7.34 +/- 0.8 x 10(6) M-1.s-1) directly measured. Thus, VIIa.TF is inhibited at near diffusion-limited rates by Xa.TFPI formed during catalysis which cannot be explained by studies of the isolated reaction. We propose that the predominant inhibitory pathway during factor X activation may involve the initial inhibition of factor Xa either bound to or in the near vicinity of VIIa.TF on the membrane surface. As a result, VIIa.TF inhibition is unexpectedly rapid, and the concentration of active factor Xa that escapes regulation is linearly dependent on the availability of TF.
Yang C, Shorey-Kendrick L, Puy C, Benson A, Wilmarth P, Reddy A Res Pract Thromb Haemost. 2025; 9(1):102676.
PMID: 40070370 PMC: 11894163. DOI: 10.1016/j.rpth.2024.102676.
A new look at TFPI inhibition of factor X activation.
Santiago F, Kaur A, Bride S, Monroe D, Leiderman K, Sindi S PLoS Comput Biol. 2024; 20(11):e1012509.
PMID: 39546494 PMC: 11567595. DOI: 10.1371/journal.pcbi.1012509.
Bhargavan B, Kanmogne G Int J Mol Sci. 2023; 24(16).
PMID: 37628764 PMC: 10454213. DOI: 10.3390/ijms241612585.
Chung D, Bakshi S, van der Graaf P Pharmaceutics. 2023; 15(3).
PMID: 36986779 PMC: 10054658. DOI: 10.3390/pharmaceutics15030918.
The Tissue Factor Pathway in Cancer: Overview and Role of Heparan Sulfate Proteoglycans.
Hassan N, Efing J, Kiesel L, Bendas G, Gotte M Cancers (Basel). 2023; 15(5).
PMID: 36900315 PMC: 10001432. DOI: 10.3390/cancers15051524.